Clinical trial
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With…
NCT00171899 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171899 |
|---|---|
| Title | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) |
| Official title | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 80 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 23, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: